By Ludwig Burger FRANKFURT (Reuters) -Development of a new cancer treatment pioneered by Roche was thrown into doubt on Wednesday when the immunotherapy drug failed to slow...
By Jonathan Stempel (Reuters) - A former chief financial officer of a New Jersey biotechnology company has been indicted for insider trading after allegedly giving his girlfriend...
By Deena Beasley (Reuters) - Gilead Sciences Inc (NASDAQ:GILD) on Thursday said its first-quarter revenue rose 3%, helped by sales of HIV drug Biktarvy and COVID antiviral...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
Wall Street seems to have eyes only for two things at the moment: the potential next move by the Federal Reserve and geopolitical tensions between Russia and Ukraine. Meanwhile,...
ABBV faces a significant loss of revenue beginning in 2023 from Humira biosimilarsFor now, the company is turning in steady earnings growthWall Street consensus outlook is...
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 75.25 | 76.44 | 73.27 | -0.49 | -0.65% | 7.32M | NYSE | |||
| 8.30 | 8.50 | 8.10 | -0.04 | -0.48% | 6.21M | NYSE | |||
| 38.08 | 38.86 | 37.53 | +0.14 | +0.37% | 6.85M | NYSE | |||
| 1.13 | 1.1514 | 1.07 | 0.0000 | 0.00% | 6.29M | NYSE | |||
| 0.185 | 0.1999 | 0.1824 | -0.0135 | -6.80% | 2.27M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 47.20 | 47.88 | 45.96 | +0.87 | +1.88% | 4.11M | NYSE | |||
| 181.89 | 197.55 | 176.72 | -14.18 | -7.23% | 1.90M | NYSE | |||
| 11.74 | 12.16 | 11.54 | -0.40 | -3.29% | 24.56M | NYSE | |||
| 47.74 | 50.20 | 43.49 | +0.03 | +0.06% | 1.14M | NASDAQ | |||
| 23.27 | 25.14 | 22.53 | -0.34 | -1.44% | 15.20M | NYSE | |||
| 1,771.68 | 1,886.53 | 1,703.32 | -117.71 | -6.23% | 443.06K | NYSE | |||
| 52.64 | 55.28 | 49.65 | -1.04 | -1.94% | 5.53M | NASDAQ | |||
| 187.60 | 199.00 | 183.25 | -13.73 | -6.82% | 4.56M | NYSE | |||
| 36.21 | 36.31 | 35.64 | +0.46 | +1.29% | 4.56M | NYSE |